Literature DB >> 23148776

Structural basis for progression toward the carbapenemase activity in the GES family of β-lactamases.

Clyde A Smith1, Hilary Frase, Marta Toth, Malika Kumarasiri, Kwame Wiafe, Jared Munoz, Shahriar Mobashery, Sergei B Vakulenko.   

Abstract

Carbapenem antibiotics have become therapeutics of last resort for the treatment of difficult infections. The emergence of class-A β-lactamases that have the ability to inactivate carbapenems in the past few years is a disconcerting clinical development in light of the diminished options for treatment of infections. A member of the GES-type β-lactamase family, GES-1, turns over imipenem poorly, but the GES-5 β-lactamase is an avid catalyst for turnover of this antibiotic. We report herein high-resolution X-ray structures of the apo GES-5 β-lactamase and the GES-1 and GES-5 β-lactamases in complex with imipenem. The latter are the first structures of native class-A carbapenemases with a clinically used carbapenem antibiotic in the active site. The structural information is supplemented by information from molecular dynamics simulations, which collectively for the first time discloses how the second step of catalysis by these enzymes, namely, hydrolytic deacylation of the acyl-enzyme species, takes place effectively in the case of the GES-5 β-lactamase and significantly less so in GES-1. This information illuminates one evolutionary path that nature has taken in the direction of the inexorable emergence of resistance to carbapenem antibiotics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23148776      PMCID: PMC3610538          DOI: 10.1021/ja308197j

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  13 in total

Review 1.  How beta-lactamases have driven pharmaceutical drug discovery. From mechanistic knowledge to clinical circumvention.

Authors:  K Bush; S Mobashery
Journal:  Adv Exp Med Biol       Date:  1998       Impact factor: 2.622

Review 2.  Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae.

Authors:  Karen Bush
Journal:  Curr Opin Microbiol       Date:  2010-10-01       Impact factor: 7.934

3.  A standard numbering scheme for the class A beta-lactamases.

Authors:  R P Ambler; A F Coulson; J M Frère; J M Ghuysen; B Joris; M Forsman; R C Levesque; G Tiraby; S G Waley
Journal:  Biochem J       Date:  1991-05-15       Impact factor: 3.857

Review 4.  Carbapenemases: the versatile beta-lactamases.

Authors:  Anne Marie Queenan; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

5.  Structure of the imipenem-hydrolyzing class A beta-lactamase SME-1 from Serratia marcescens.

Authors:  Wladimir Sougakoff; Guillaume L'Hermite; Lucile Pernot; Thierry Naas; Valérie Guillet; Patrice Nordmann; Vincent Jarlier; Jean Delettré
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2002-01-24

6.  Ab initio QM/MM study of class A beta-lactamase acylation: dual participation of Glu166 and Lys73 in a concerted base promotion of Ser70.

Authors:  Samy O Meroueh; Jed F Fisher; H Bernhard Schlegel; Shahriar Mobashery
Journal:  J Am Chem Soc       Date:  2005-11-09       Impact factor: 15.419

7.  Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.

Authors:  Todd A Davies; Anne Marie Queenan; Brian J Morrow; Wenchi Shang; Karen Amsler; Wenping He; A Simon Lynch; Chris Pillar; Robert K Flamm
Journal:  J Antimicrob Chemother       Date:  2011-07-20       Impact factor: 5.790

8.  Inhibition of class A beta-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1.

Authors:  Michiyosi Nukaga; Christopher R Bethel; Jodi M Thomson; Andrea M Hujer; Anne Distler; Vernon E Anderson; James R Knox; Robert A Bonomo
Journal:  J Am Chem Soc       Date:  2008-08-30       Impact factor: 15.419

Review 9.  Class A carbapenemases.

Authors:  Jan Walther-Rasmussen; Niels Høiby
Journal:  J Antimicrob Chemother       Date:  2007-06-26       Impact factor: 5.790

10.  Mechanistic basis for the emergence of catalytic competence against carbapenem antibiotics by the GES family of beta-lactamases.

Authors:  Hilary Frase; Qicun Shi; Sebastian A Testero; Shahriar Mobashery; Sergei B Vakulenko
Journal:  J Biol Chem       Date:  2009-08-05       Impact factor: 5.157

View more
  19 in total

1.  Kinetic characterization of GES-22 β-lactamase harboring the M169L clinical mutation.

Authors:  Aysegul Saral; David A Leonard; Azer Ozad Duzgun; Aysegul Copur Cicek; Cynthia M June; Cemal Sandalli
Journal:  J Antibiot (Tokyo)       Date:  2016-05-11       Impact factor: 2.649

2.  First virtual screening and experimental validation of inhibitors targeting GES-5 carbapenemase.

Authors:  Francesca Spyrakis; Pierangelo Bellio; Antonio Quotadamo; Pasquale Linciano; Paolo Benedetti; Giulia D'Arrigo; Massimo Baroni; Laura Cendron; Giuseppe Celenza; Donatella Tondi
Journal:  J Comput Aided Mol Des       Date:  2019-01-02       Impact factor: 3.686

3.  In vitro prediction of the evolution of GES-1 β-lactamase hydrolytic activity.

Authors:  Séverine Bontron; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2015-01-05       Impact factor: 5.191

4.  Role of the Conserved Disulfide Bridge in Class A Carbapenemases.

Authors:  Clyde A Smith; Zahra Nossoni; Marta Toth; Nichole K Stewart; Hilary Frase; Sergei B Vakulenko
Journal:  J Biol Chem       Date:  2016-09-02       Impact factor: 5.157

5.  P174E Substitution in GES-1 and GES-5 β-Lactamases Improves Catalytic Efficiency toward Carbapenems.

Authors:  Alessandra Piccirilli; Paola Sandra Mercuri; Moreno Galleni; Massimiliano Aschi; André Matagne; Gianfranco Amicosante; Mariagrazia Perilli
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

6.  Mechanism of proton transfer in class A β-lactamase catalysis and inhibition by avibactam.

Authors:  Orville A Pemberton; Radwan E Noor; Vasantha Kumar M V; Ruslan Sanishvili; M Trent Kemp; Fiona L Kearns; H Lee Woodcock; Ioannis Gelis; Yu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-02       Impact factor: 11.205

7.  Molecular Basis for the Potent Inhibition of the Emerging Carbapenemase VCC-1 by Avibactam.

Authors:  Chand S Mangat; Grishma Vadlamani; Viktor Holicek; Mitchell Chu; Veronica L C Larmour; David J Vocadlo; Michael R Mulvey; Brian L Mark
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 8.  β-Lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates.

Authors:  Montserrat Mora-Ochomogo; Christopher T Lohans
Journal:  RSC Med Chem       Date:  2021-08-04

9.  Modified Penicillin Molecule with Carbapenem-Like Stereochemistry Specifically Inhibits Class C β-Lactamases.

Authors:  Xuehua Pan; Yunjiao He; Tianfeng Chen; Kin-Fai Chan; Yanxiang Zhao
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

10.  Inhibition of the Clostridioides difficile Class D β-Lactamase CDD-1 by Avibactam.

Authors:  Nichole K Stewart; Marta Toth; Anastasiya Stasyuk; Mijoon Lee; Clyde A Smith; Sergei B Vakulenko
Journal:  ACS Infect Dis       Date:  2021-01-03       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.